
Marios Georgakis: Why Did Two Major Clinical Trials for Heart Disease Fail?
In recent weeks the results (announced by press release) of 2 major placebo-controlled randomized trials—ZEUS, testing an interleukin-6 (IL-6) blocker vs inflammation, and HORIZON, testing a drug to lower Lp(a), indicated failure to achieve their primary endpoint. Are we maxxed out for new treatments vs heart disease, as this article in the WSJ (←gift link) today asserts? “Cardiovascular drug development is starting to look a bit like the modern oil industry. The easy wells have been tapped. What’s left is in deep water: expensive, technically perilous and less likely to strike oil.” Or is it more complicated? Are the trial results and reasons for failure different? I wrote a recent Ground Truths —The Coronary Artery Inflammation Controversy— on the data (what has been released to date) and my take. But I wanted to vet this with another physician-scientist who is studying atherosclerosis and turned to Prof Marios Georgakis, from the University of Munich, who as I mentioned in the previous piece, wrote a brilliant analysis of ZEUS and is also doing writing about HORIZON. Many years ago we went through a “CV winter” when the biopharma companies largely shunned doing clinical trials for heart disease. They thought the field had been maxxed out. After a lapse of several years, there have many trials undertaken with positive results and substantial progress for better treatments vs heart disease.
Publisher
Ground Truths
Link
erictopol.substack.com/p/why-did-two-major-clinical-trials
Published
September 14, 2026
Duration
1h 8m
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Eric Topol
Ground Truths
@groundtruths
#mariosgeorgakis #majorclinicaltrials #heartdiseasefail #lifesciences #medicine
